{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:26Z","timestamp":1783075946122,"version":"3.54.6"},"reference-count":58,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s235104","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T03:03:42Z","timestamp":1598324622000},"page":"1541-1551","source":"Crossref","is-referenced-by-count":21,"title":["<p>Transdermal Asenapine in Schizophrenia: A Systematic Review<\/p>"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Brennan","family":"Carrithers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rif S","family":"El-Mallakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8]]},"reference":[{"key":"ref1","unstructured":"United Ststes Food and Drug Administration (USFDA). Press Announcements: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder; 2009. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm177401.html. Accessed June 29 2020."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"18nr12554","DOI":"10.4088\/JCP.18nr12554","volume":"80","author":"Citrome","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Citrome L, Walling D, Zeni C, Komaroff M, Park A Efficacy and safety of an asenapine transdermal system (HP-3070) for treatment of adults with schizophrenia: a Phase 3 randomized, placebo-controlled, inpatient study. Presented at: Psych Congress 2019; October 3-6, 2019; San Diego, CA. Poster 122.","DOI":"10.1016\/j.biopsych.2019.03.315"},{"key":"ref4","unstructured":"Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene. WO2018115010A1; 2018."},{"key":"ref5","unstructured":"Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, applicant. Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer. WO2019002204A1; 2019."},{"key":"ref6","unstructured":"Mohr P, Rietscher R, Eifler R, Bourquain O, inventors. LTS Lohmann Therapie-Systeme AG, Andernach, Germany, appli- cant. Transdermal therapeutic system containing asenapine. WO2018115001A1; 2018."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/08982104.2015.1098659","volume":"26","author":"Shreya","year":"2016","journal-title":"J Liposome Res"},{"key":"ref8","volume-title":"Transdermal Compositions of Asenapine for the Treatment of Psychiatric Disorders. WO2010127674A1","year":"2010"},{"key":"ref9","unstructured":"Suzuki M, Okutsu H, Yasukochi T, Takada Y; inventors. Assignee. Patch. US20170172981A1. Tosu-shi: Hisamitsu Pharmaceutical Co., Inc.; 2017."},{"key":"ref10","unstructured":"Suzuki M, Okutsu H, Yasukochi T, Takada Y; inventors. Assignee. Patch US20180360968A1. Tosu-shi, Japan: Hisamitsu Pharmaceutical Co., Inc; 2018."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1124\/dmd.110.036715","volume":"39","author":"van de Wetering-krebbers","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jpba.2017.07.037","volume":"145","author":"Lu","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.24869\/psyd.2019.157","volume":"31","author":"Reyad","year":"2019","journal-title":"Psychiatr Danub"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/17425255.2014.908185","volume":"10","author":"Citrome","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref15","unstructured":"Center for Drug Evaluation and Research (CDER). SAPHRIS\u00ae (asenapine) Sublingual Tablets, Chemistry Review(s) \u2013 access data FDA; NDA 22-117, 2009. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022117s000_ChemR.pdf. Accessed 20 March 2020."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3389\/fphar.2019.01328","volume":"10","author":"Hua","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"18nr02412","DOI":"10.4088\/PCC.18nr02412","volume":"21","author":"El-Mallakh","year":"2019","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat Biotechnol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-019-00659-7","volume":"33","author":"Abruzzo","year":"2019","journal-title":"CNS Drugs"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/1060028015583893","volume":"49","author":"Kaminsky","year":"2015","journal-title":"Ann Pharmacother"},{"key":"ref21","unstructured":"Secuado (asenapine) [prescribing information]. Miami, FL. Noven Therapeutics, LLC; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212268s000lbl.pdf. Accessed May 15, 2020."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/s12248-010-9247-4","volume":"13","author":"de Greef","year":"2011","journal-title":"AAPS J"},{"key":"ref23","unstructured":"Food and Drug Administration. NDA\/BLA Multi-disciplinary Review and Evaluation NDA 212268 Secuado (asenapine) transdermal system. 2018. Available from: https:\/\/www.fda.gov\/media\/124109\/download. accessed April 3, 2020."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","volume":"122","author":"McIntyre","year":"2010","journal-title":"J Affect Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s00213-016-4295-9","volume":"233","author":"Kinoshita","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1017\/S1092852916000377","volume":"22","author":"Landbloom","year":"2017","journal-title":"CNS Spectr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2174\/0929867323666160525115014","volume":"23","author":"Marazziti","year":"2019","journal-title":"Curr Medicinal Chem"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.euroneuro.2008.11.001","volume":"19","author":"Ghanbari","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.mehy.2012.10.014","volume":"80","author":"El-Mallakh","year":"2013","journal-title":"Med Hypotheses"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/acps.12262","volume":"130","author":"Pratts","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"ref34","first-page":"27","volume":"47","author":"Amon","year":"2017","journal-title":"Psychopharmacol Bull"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40263-017-0458-4","volume":"31","author":"Bozzatello","year":"2017","journal-title":"CNS Drugs"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.2147\/NDT.S149376","volume":"13","author":"Citrome","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.biopsych.2005.05.012","volume":"58","author":"Hedlund","year":"2005","journal-title":"Biol Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.neuropharm.2006.04.017","volume":"51","author":"Wesolowska","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jad.2019.11.031","volume":"264","author":"Wang","year":"2020","journal-title":"J Affect Disord"},{"key":"ref40","first-page":"8","volume":"50","author":"El-Mallakh","year":"2020","journal-title":"Psychopharmacol Bull"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"10507","DOI":"10.3390\/molecules161210507","volume":"16","author":"Fox","year":"2011","journal-title":"Molecules"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4155\/tde.10.16","volume":"1","author":"Paudel","year":"2010","journal-title":"Ther Deliv"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3109\/03639045.2011.597765","volume":"38","author":"Borovinskaya","year":"2012","journal-title":"Drug Dev Ind Pharm"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.3390\/pharmaceutics10020051","volume":"10","author":"Ng","year":"2018","journal-title":"Pharmaceutics"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/NDT.S34433","volume":"9","author":"Tenjin","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref46","unstructured":"Sumitomo Dainippon Pharma Co., Ltd., Long-term study of DSP- 5423P in Patients with Schizophrenia. ClinicalTrials.gov identifier NCT02335658; 2014. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02335658?term=DSP5423P&cntry=JP&rank=1. Accessed 15 May 2020.."},{"key":"ref47","unstructured":"Sonobe A, Yasukochi T, Takada Y; inventors. Assignee. Patch US20180289631A1. Tosu-shi, Japan: Hisamitsu Pharmaceutical Co., Inc.; 2018."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1517\/14656566.2010.506188","volume":"11","author":"Minassian","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/acps.12952","volume":"138","author":"\u00d8stergaard","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Citrome L, Walling D, Zeni C, Komaroff M, Park A Efficacy and safety of an asenapine transdermal system (Asenapine Transdermal System, HP-3070) in the treatment of adults with schizophrenia: a Phase 3 randomized, double-blind, placebo-controlled, 6-week inpatient study. Presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology, December 9\u201313, 2018, Hollywood, Florida","DOI":"10.1016\/j.biopsych.2019.03.315"},{"key":"ref53","unstructured":"Citrome L, Walling D, Zeni C, Komaroff M, Park A HP-3070 asenapine transdermal system in adults with schizophrenia: categorical response and clinical relevance as assessed in a Phase 3 RCT. Presented at the Annual American Psychiatric Association Meeting, May 18\u201322, 2019, San Francisco, CA, USA"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","volume":"63","author":"Citrome","year":"2009","journal-title":"Int J Clin Pract"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41386-019-0363-2","volume":"44","author":"Leucht","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.2147\/NDT.S130211","volume":"13","author":"Durgam","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/JCP.0000000000000271","volume":"35","author":"Worthington","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"180","DOI":"10.9740\/mhc.2015.07.180","volume":"5","author":"Sweet","year":"2015","journal-title":"Ment Health Clin"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=61034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=61034","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T03:03:55Z","timestamp":1598324635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/transdermal-asenapine-in-schizophrenia-a-systematic-review-peer-reviewed-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":58,"URL":"https:\/\/doi.org\/10.2147\/ppa.s235104","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}